Investigation of the Presbia Flexivue Microlens™

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by PresbiBio, LLC
Sponsor:
Information provided by (Responsible Party):
PresbiBio, LLC
ClinicalTrials.gov Identifier:
NCT02110472
First received: April 8, 2014
Last updated: March 31, 2015
Last verified: March 2015
  Purpose

The Presbia Flexivue Microlens is a corneal inlay.


Condition Intervention Phase
Presbyopia
Device: Corneal inlay
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Prospective, Non-randomized, Unmasked, Multicenter Clinical Investigation of the Presbia Flexivue Microlens™ for the Improvement of Near Vision in Emmetropic Presbyopes

Further study details as provided by PresbiBio, LLC:

Primary Outcome Measures:
  • Uncorrected near visual acuity - operated eyes [ Time Frame: 24 months postoperative ] [ Designated as safety issue: No ]
    Uncorrected near visual acuity at 40 cm of 20/40 or better


Secondary Outcome Measures:
  • Uncorrected near visual acuity - operated eyes [ Time Frame: 24 months postoperative ] [ Designated as safety issue: No ]
    - Number of lines of improvement uncorrected near visual acuity


Other Outcome Measures:
  • Adverse Events [ Time Frame: 24 months postoperative ] [ Designated as safety issue: Yes ]
    - Rate of operated eyes with best corrected distance visual acuity 20/40 or worse


Estimated Enrollment: 412
Study Start Date: May 2014
Estimated Study Completion Date: February 2019
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Presbia Flexivue Microlens Corneal Inlay
Presbia Flexivue Microlens implanted in corneal pocket in nondominant eye
Device: Corneal inlay
Presbia Flexivue Microlens implantation in corneal pocket created in nondominant eyes of emmetropic presbyopes.
Other Names:
  • Presbia Flexivue Microlens
  • Presbia Microlens

Detailed Description:

Presbyopia is a multifactorial physiological aging mechanism that leads to a progressive functional loss of near vision. In addition to the use of reading glasses for presbyopia, a wide variety of procedures have been investigated by ophthalmologists to correct this refractive error. Cornea laser surgery with multifocal patterns or monovision approaches were developed including LASIK, PresbyLASIK, photorefractive keratectomy (PRK), laser epithelial keratomileusis (LASEK), thin-flap femto-LASIK or sub-Bowman's keratomileusis (SBK). Conductive keratoplasty (CK), clear lens extraction or cataract surgery using multifocal, pseudo-accommodative intraocular lenses (IOLs) or monovision monofocal IOLs are also some of the techniques that have been used for the treatment of presbyopia.

Corneal laser surgery and CK are minimally invasive methods, but they provoke irreversible changes of the corneal anatomy, whereas scleral surgery and clear lens extraction are more invasive techniques. The necessity to develop a minimally invasive, reversible, and safe surgical technique with an easy learning curve for patients between 45 and 60 years, led to the development of refractive intracorneal lenses (inlays) (such as the AcuFocus, Inc. KAMRA™, ReVision Optics® PresbyLens®, and the Presbia Flexivue Microlens™) placed inside the corneal stroma. These inlays are refractive lenses that have a central zone free of refractive power and a peripheral zone with a standard positive refractive power. These inlays are inserted inside the corneal stroma of the non-dominant eye, generally offering two different focal points, one for the far vision and a different for the near vision respectively. The pocket of the cornea is created using a laser (details to be provided later in this protocol).

The Presbia Flexivue Microlens is intended to improve near vision and decrease dependence on reading glasses in presbyopic adults who are tolerant of monovision (as evaluated by participation in a monovision tolerance trial (5 to 7 days minimum)), who require a reading add of +1.50 D to +3.50 D, who have MRSE between +1.00 D and 0.75 D with no more than 0.75 D of refractive cylinder, and who have stable MRSE within 0.50 D over the past 12 months.

Objective: The primary objective of this study is to evaluate the safety and effectiveness of the Presbia Flexivue Microlens™ (hereinafter referred to as the "Microlens") implanted in presbyopes for improvement of near vision.

Investigational Plan: This is a prospective, non-randomized, unmasked, multicenter clinical investigation. A total of 412 subjects at up to 11 investigational sites in the United States will undergo insertion of the Microlens in non-dominant eyes, and will be followed through 36 months postoperative (assuming an estimated 10% per year lost to follow-up). Each site will contribute a targeted minimum of 20 treated subjects, but no more than 25% of the total subjects treated in the study. Data on a minimum of 300 subjects with 24 month data will be submitted as part of the Premarket Approval; all subjects will be followed through 36 months postoperative. Subjects from outside the United States will not be enrolled in this study.

  Eligibility

Ages Eligible for Study:   45 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects must be emmetropes with presbyopia, between ≥ 45 years and ≤ 60 years of age at time of eligibility visit.
  • Subjects must need a reading add of +1.50 D to +3.50 D.
  • Subjects must have uncorrected near visual acuity of 20/50 or worse.
  • Subjects must have near visual acuity correctable to 20/20 or better in each eye.
  • Subjects must have distance visual acuity correctable to 20/25 or better in each eye.
  • Subjects must have a preoperative spherical equivalent of +1.00 D to -0.75 D with no more than 0.75 D of refractive cylinder as determined by cycloplegic refraction in each eye.
  • Subjects must have a photopic pupil size of > 1.6 mm in the eye to be implanted.

Exclusion Criteria:

  • Subjects in whom the non-dominant eye cannot be determined using one of the methods identified in the test of ocular dominance.
  • Subjects who do not complete the monovision tolerance trial (minimum of 5 to 7 days).
  • Subjects who report that they were not completely satisfied with their vision during the monovision tolerance trial.
  • Subjects who report that they experienced debilitating or significant visual symptoms such as halos, glare, double vision, etc. during the monovision tolerance trial.
  • Subjects with a difference of ≥ 1.00 D between the spherical equivalent manifest refraction and the spherical equivalent cycloplegic refraction.
  • Subject with a preferred near working distance of < 35 cm or > 45 cm.
  • Subjects with corneal thickness < 500 microns in the eye to be implanted.
  • Subjects with clinically significant anterior segment pathology, including cataracts, in either eye.
  • Subjects with residual, recurrent, active ocular or uncontrolled eyelid disease or any progressive corneal abnormalities (including endothelial dystrophy, guttata in the central cornea, etc.) in the eye to be treated.
  • Subjects with keratoconus (or keratoconus suspect), amblyopia, recurrent erosion syndrome or corneal dystrophy in the eye to be treated.
  • Subjects with a history of chronic dry eye not controlled on therapy or with superficial punctuate keratitis (SPK) grade > II (i.e., greater than mild) based on Oxford Grading Scale in the eye to be treated.
  • Subjects with abnormal corneal mires on topography maps of the eye to be treated.
  • Subjects who require canthotomy to generate a corneal tunnel in the eye to be treated.
  • Subjects with progressive retinal pathology with a reasonable chance of causing a reduction in BCVA from preoperative in the eye to be treated.
  • Subjects who have undergone previous intraocular or corneal surgery including cataract and refractive surgery (e.g., LASIK surgery) in either eye.
  • Subjects using ophthalmic medication(s) other than artificial tears for treatment of ocular pathology.
  • Subjects with a history of autoimmune disease, connective tissue disease, or clinically significant atopic syndrome.
  • Subjects with a history of herpes zoster or herpes simplex keratitis.
  • Subjects with a history of steroid-responsive rise in intraocular pressure (IOP), or a preoperative IOP > 21 mmHg or glaucoma.
  • Subjects with distorted, non-reactive, or decentered pupils.
  • Subjects taking medication for the control of diabetes.
  • Subjects on chronic systemic or topical corticosteroids or other immunosuppressive therapy that may affect wound healing, and any immuno-compromised subjects (use of intranasal steroids for seasonal allergies are acceptable).
  • Subjects using systemic medications (e.g., amiodarone) or medications with significant ocular side effects.
  • Subjects who are pregnant, or are considering becoming pregnant during the time of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02110472

Contacts
Contact: Vanessa A Tasso 949-502-7025 Vanessa@presbia.com
Contact: Priscilla Gottron 949-502-7023 Priscilla@presbia.com

Locations
United States, California
Assil Eye Institute Recruiting
Beverly Hills, California, United States, 90210
Contact: Lindsay Harris, OD    310-453-8911      
Contact: Emily Vogel, OD         
Principal Investigator: Kerry Assil, MD         
Sub-Investigator: Lindsay Harris, OD         
Sub-Investigator: Emily Vogel, OD         
Gordon-Weiss-Schanzlin Recruiting
La Jolla, California, United States, 92122
Contact: Elizabeth Medina, COT    858-455-6800      
Principal Investigator: Michael Gordon, MD         
Maloney Vision Institute Recruiting
Los Angeles, California, United States, 90024
Contact: Blanca Salter    310-208-3937      
Principal Investigator: Robert K Maloney, MD, MA         
Stanford Eye and Laser Center Recruiting
Palo Alto, California, United States, 94303
Contact: Ryan Berroya    650-725-5765      
Principal Investigator: Edward Manche, MD         
United States, Florida
Center for Sight Recruiting
Sarasota, Florida, United States, 34239
Contact: Ginger Moritz    941-925-2020      
Principal Investigator: William Lahners, MD         
United States, Illinois
Kraft Eye Institute Recruiting
Chicago, Illinois, United States, 60602
Contact: Monica Watson    312-444-1111      
Principal Investigator: Coleman Kraff, MD         
United States, North Carolina
Physicians Protocol Recruiting
Greensboro, North Carolina, United States, 27410
Contact: Tori Pleasants    336-288-8823      
Principal Investigator: Karl Stonecipher, MD         
United States, Ohio
Cleveland Eye Clinic Recruiting
Brecksville, Ohio, United States, 44141
Contact: Karen Keaton    440-526-1974      
Contact: Amelia Bunce    (440) 526-1974      
Principal Investigator: Shamik Bafna, MD         
United States, Texas
Berkeley Eye and Laser Center Recruiting
Houston, Texas, United States, 77027
Contact: Bobby Perez, COT    713-526-3937      
Principal Investigator: Michael Caplan, MD         
United States, Utah
Hoopes Vision, Laser Correction Center Recruiting
Draper, Utah, United States, 84020
Contact: Steve Linn, OD    801-568-0200      
Principal Investigator: Robert Rivera, MD         
Sub-Investigator: Philip C Hoopes, MD         
Sub-Investigator: Philip C Hoopes, Jr, MD         
Sub-Investigator: Michael J Bradley, MD         
United States, Virginia
The Eye Center Recruiting
Fairfax, Virginia, United States, 22031
Contact: Rachel Crage    703-573-8080      
Contact: Julie Hoggat    (703) 573-8080      
Principal Investigator: Ayman Boutros, MD         
Sponsors and Collaborators
PresbiBio, LLC
Investigators
Study Director: Robert K Maloney, MD, MA Maloney Vision Institute
Study Director: Mickey Gordon, MD Gordon-Weiss-Schanzlin Vision Institute
  More Information

Additional Information:
No publications provided

Responsible Party: PresbiBio, LLC
ClinicalTrials.gov Identifier: NCT02110472     History of Changes
Other Study ID Numbers: CLP-12-001
Study First Received: April 8, 2014
Last Updated: March 31, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by PresbiBio, LLC:
Emmetropic presbyopes
Presbyopic

Additional relevant MeSH terms:
Presbyopia
Eye Diseases
Refractive Errors

ClinicalTrials.gov processed this record on July 29, 2015